Paradigm Therapeutics Ltd acquires Amedis Pharmaceuticals Ltd
New financing to accelerate drug discovery
Paradigm Therapeutics Ltd announced that it has completed the acquisition of Amedis Pharmaceuticals Ltd., a medicinal chemistry and drug discovery company. The transaction will create an enlarged company with a unique mix of proprietary biology and chemistry capabilities. The Company will focus on identifying highly druggable targets and novel compounds for conditions in the areas of CNS, pain, endocrinology and metabolism. It has two programmes in late stage pre-clinical development as well as a number of earlier stage programmes and opportunities. Post-merger, the Company's growth plans will see it grow by around 30% between the UK and the Singapore operations. The Company is located in Cambridge Science Park, UK and has a wholly owned subsidiary, Paradigm Therapeutics Singapore Pte Ltd., based at the Biopolis in Singapore.
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.